Selpercatinib is one of the new and latest additions to the FDA approved medications for non-small cell lung cancer treatment. This oral medication is also recommended in the management of medullary thyroid cancer. The specific indication or setting for the treatment with Selpercatinib would include metastatic RET fusion-positive cases. Retevmo is the commercial name for this drug. Eli Lilly is credited for its development and is also responsible for its worldwide promotions. Selpercatinib in India is an option given by the Oncologists for the patients who consider import possibilities.

Retevmo 40mg and Retevmo 80mg capsules are commercially available in the US and Europe. RET gene alteration has to be established before prescribing this drug. Selpercatinib is arguably the first of its kind medication, approved in this specific setting of cancer treatment. In NSCLC, it is indicated only for adult patients. In case of thyroid cancer and medullary thyroid cancer, patients above twelve years are eligible for the treatment.

Selpercatinib was given its FDA approval in 2020. It is considered to be a very promising therapeutic option in the treatment of lung and thyroid cancers. The ongoing clinical research further expands the scope and possibility for its approval in new indications too. The dosage is determined by the body weight. Below 50 KG and above 50 KG are the two basic criteria used to determine the dosage.